IRIS
BRAVACCINI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.227
AS - Asia 1.613
EU - Europa 832
SA - Sud America 601
AF - Africa 48
OC - Oceania 2
Totale 6.323
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.157
SG - Singapore 728
BR - Brasile 519
HK - Hong Kong 396
IE - Irlanda 312
IT - Italia 145
VN - Vietnam 140
CN - Cina 107
DE - Germania 96
TR - Turchia 61
FR - Francia 52
IN - India 43
GB - Regno Unito 39
BD - Bangladesh 36
NL - Olanda 35
AR - Argentina 33
FI - Finlandia 30
MX - Messico 28
CA - Canada 27
RU - Federazione Russa 25
IQ - Iraq 21
AT - Austria 16
UA - Ucraina 13
CO - Colombia 12
ID - Indonesia 12
PK - Pakistan 12
EC - Ecuador 11
ES - Italia 11
LT - Lituania 11
PL - Polonia 11
ZA - Sudafrica 11
UZ - Uzbekistan 10
SE - Svezia 9
SA - Arabia Saudita 8
TN - Tunisia 8
BE - Belgio 7
JP - Giappone 7
PY - Paraguay 7
CL - Cile 6
CZ - Repubblica Ceca 6
EG - Egitto 6
KE - Kenya 6
MA - Marocco 6
IL - Israele 5
VE - Venezuela 5
AL - Albania 4
CR - Costa Rica 4
PH - Filippine 4
SN - Senegal 4
UY - Uruguay 4
AZ - Azerbaigian 3
BO - Bolivia 3
JO - Giordania 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BH - Bahrain 2
DZ - Algeria 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
MY - Malesia 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HU - Ungheria 1
IS - Islanda 1
KZ - Kazakistan 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
TH - Thailandia 1
UG - Uganda 1
Totale 6.323
Salva come PNG Salva come JPEG
Città #
Dallas 1.337
San Jose 442
Singapore 399
Hong Kong 394
Dublin 312
Ashburn 291
The Dalles 171
Chicago 159
Santa Clara 139
Boardman 137
São Paulo 52
Ho Chi Minh City 49
Istanbul 46
Munich 38
Assago 32
Helsinki 26
Beijing 25
Amsterdam 24
Rio de Janeiro 23
Hanoi 22
Los Angeles 22
Frankfurt am Main 20
Milan 18
New York 16
Brasília 13
Belo Horizonte 10
Boston 10
Düsseldorf 10
Haiphong 10
Orem 10
San Francisco 10
Vienna 10
Chennai 9
Montreal 9
Porto Alegre 9
Tashkent 9
Warsaw 9
Hillsboro 8
Rome 8
Brooklyn 7
Buenos Aires 7
Campinas 7
Guarulhos 7
Manchester 7
Mexico City 7
Palermo 7
Paris 7
Quito 7
Ankara 6
Bexley 6
Brno 6
Brussels 6
Council Bluffs 6
Curitiba 6
Lahore 6
Riyadh 6
Salvador 6
Tokyo 6
Toronto 6
Atlanta 5
Baghdad 5
Lugo 5
Nairobi 5
New Delhi 5
Nuremberg 5
Ottawa 5
Ribeirão Preto 5
Stockholm 5
Thái Bình 5
Asunción 4
Betim 4
Bogotá 4
Charlotte 4
Contagem 4
Da Nang 4
Dakar 4
Dhaka 4
Florence 4
Hải Dương 4
Johannesburg 4
Juiz de Fora 4
London 4
Mumbai 4
Passo Fundo 4
Piracicaba 4
Roubaix 4
Sorocaba 4
Tel Aviv 4
Teresina 4
Turin 4
Atibaia 3
Baku 3
Basra 3
Birmingham 3
Biên Hòa 3
Cairo 3
Cape Town 3
Catania 3
Delhi 3
Denver 3
Totale 4.631
Salva come PNG Salva come JPEG
Nome #
The current status of biomarkers for bladder cancer: progress and challenges 143
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 91
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. 89
Expanding the Horizon of Multidisciplinarity: Incorporating Biomechanical, Metabolic, and Functional Factors Into Registry-Based Research to Predict Subsequent Risk for Total Knee Arthroplasty 78
Biomarkers: which ones do we really need today? 75
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution 73
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study 69
The use of platelets as a clinical tool in oncology: opportunities and challenges 69
Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer 69
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors 69
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 67
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 63
Urinary Biomarkers in Tumors: An Overview 62
Letter to the Editor discussing: Hacker S, Lenz C, Reichert L, Ringseis R, Zentgraf K, Krüger K. Vitamin D status and its determinants in German elite athletes. Eur J Appl Physiol. 2025 Jan 4. doi: 10.1007/s00421-024–05699-6 61
Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update 61
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 59
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) 58
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 56
FAP inhibitors: are we really using the best method to evaluate the residence time? 56
Androgen receptor signaling pathways as a target for breast cancer treatment 56
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection 55
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients 54
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 54
Telomerase Activity Analysis In Urine Sediment for Bladder Cancer 54
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 54
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota 53
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 53
Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? 53
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer 53
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma insitu treated with surgery and radiotherapy 52
Androgen receptor in breast cancer: The "5W" questions 52
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 51
Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa 50
ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA 50
An H-1 NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 50
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 50
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 49
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? 49
Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives 49
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 48
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 48
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 48
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in patients with different subtypes of breast cancer 48
Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer 48
Are we ready to use TMB in breast cancer clinical practice? 48
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? 48
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 47
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 47
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential 47
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy 47
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity 46
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance 46
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 45
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design 45
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 45
Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients. 45
Explaining the aggressiveness of breast cancer in sub-Saharan African patients 45
Usefulness of immunological detection of the human telomerase reverse transcriptase 44
Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) 44
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer 44
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 43
TMB in NSCLC: A Broken Dream? 43
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells 43
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? 43
In-111-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance 43
Why the complications of COVID-19 patients differ in elderly and young cancer patients 43
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study 42
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. 42
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma 42
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 42
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR) 41
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 41
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report 41
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 41
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 41
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer 41
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression 41
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer" 41
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer 40
Expanding Roles of De Novo Lipogenesis in Breast Cancer 40
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis 40
Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN 40
Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro 40
New Biomarkers to Predict the Evolution of In Situ Breast Cancers 39
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 38
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 38
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country 38
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 38
Relevance of urine telomerase in the diagnosis of bladder cancer 38
Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold 38
Urine telomerase: An important marker in the diagnosis of bladder cancer 37
Role of Telomerase in Cervical Lesions as Prognostic Marker: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization 37
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 37
The current status of biomarkers for bladder cancer: progress and challenges 36
Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue 36
Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT) 36
Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches 36
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy 36
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa 35
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls 35
Totale 4.964
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.214
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.214
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024187 0 0 0 0 0 0 0 0 0 0 0 187
2024/20252.496 264 71 193 57 234 318 149 135 304 299 283 189
2025/20263.918 313 965 545 415 150 167 515 326 312 210 0 0
Totale 6.601